Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
Holding CRMD?
Track your performance easily
CRMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.57 - $13.85
Previous Close$11.6
Volume1.50M
Average Volume (3M)1.17M
Market Cap
$645.00M
Enterprise Value$599.52M
Total Cash (Recent Filing)$46.03M
Total Debt (Recent Filing)$556.00K
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Apr 01, 2025EPS Estimate
$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding60,677,204
10 Day Avg. Volume1,911,051
30 Day Avg. Volume1,168,946
Standard Deviation0.24
R-Squared0.12
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)11.96
Price to Sales (P/S)52.60
Price to Cash Flow (P/CF)-11.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue48.89
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.70
Forecast
1Y Price Target
$15.25Price Target Upside31.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Cormedix News
PremiumCompany Announcements
CorMedix Inc. Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe DefenCath launch is progressing well ahead of expectations in just the first quarter of the outpatient phase.
Sales PerformanceDefenCath's 3Q24 sales of $11.5MM were in-line with expectations, surpassing the Street's estimate of $10.3MM.
Strategic AgreementsA multi-year commercial supply agreement for DefenCath has been established with a global healthcare company, believed to be one of the two largest dialysis providers.
Bears Say
GuidanceThere is a lack of visibility on the timing of initial large dialysis operator orders, preventing more specific 4Q sales guidance.
Sales GrowthCRMD remains a 'show me story' where sustained DefenCath quarterly sales growth will be needed to drive a sustained value inflection.
Stock PerformanceCRMD shares are under pressure partly due to consolidation after a significant move since mid-August and disappointment with lack of 4Q guidance.
---
Ownership Overview
1.50% Insiders
7.88% Mutual Funds
3.05% Other Institutional Investors
78.88% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $2.57 and its highest was $13.85 in the past 12 months.
What is Cormedix’s market cap?
Currently, no data Available
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Apr 01, 2025 which is in 142 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Oct 30, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.122 by $0.072.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is $0.03.
How many shares outstanding does Cormedix have?
Cormedix has 60,677,204 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.122. Following the earnings report the stock price went down -22.513%.
Which hedge fund is a major shareholder of Cormedix?
Among the largest hedge funds holding Cormedix’s share is Elliott Investment Management LP. It holds Cormedix’s shares valued at 7M.
---
Cormedix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (31.47% Upside)
$15.25 (31.47% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
261.37%
12-Months-Change
Fundamentals
Return on Equity
-65.04%
Trailing 12-Months
Asset Growth
-15.14%
Trailing 12-Months
Company Description
Cormedix
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
---
CRMD Earnings Call
Q3 2024
0:00 / 0:00
---
CRMD Stock 12 Month Forecast
Average Price Target
$15.25
▲(31.47% Upside)
Technical Analysis
Best Analysts Covering CRMD
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+71.19%
reiterated a buy rating 11 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +71.19% per trade.
---